Highbridge Capital Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Highbridge Capital Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77.3K	Sell	857,493 -186,826	-18%	-$19.3K	﹤0.01%	329
2026 Q1	$62.6K	Buy	1,044,319 +20,207	+2%	+$2.14K	﹤0.01%	270
2025 Q4	$162K	Buy	1,024,112 +40,512	+4%	+$7.86K	0.01%	166
2025 Q3	$214K	Buy	983,600 +133,600	+16%	+$24.8K	0.01%	142
2025 Q2	$106K	Hold	850,000	–	–	﹤0.01%	183
2025 Q1	$111K	Buy	+850,000	New	+$119K	﹤0.01%	149

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Highbridge Capital Management's DMAAR Position: Q2 2026 in Review

Highbridge Capital Management reduced its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 18% in Q2 2026, selling an estimated $19.3K and leaving 857,493 shares worth $77.3K. The position accounts for ﹤0.01% of the portfolio, ranked #329.

Highbridge Capital Management first reported a position in DMAAR in Q1 2025 and has held it in 6 quarters since. The position peaked at $214K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

Highbridge Capital Management held 857,493 shares of Drugs Made In America Acquisition Corp Rights worth $77.3K as of Q2 2026.
Highbridge Capital Management sold 186,826 Drugs Made In America Acquisition Corp Rights shares in Q2 2026, an estimated $19.3K.
Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Highbridge Capital Management's portfolio in Q2 2026, its #329 holding.
Highbridge Capital Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 6 quarters since.
Highbridge Capital Management's Drugs Made In America Acquisition Corp Rights position peaked at $214K in Q3 2025.
28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Highbridge Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.